Novo Japan Sales Renew Record in 2022 as Ozempic, Rybelsus Blossom

April 12, 2023
Kasper Bødker Mejlvang Tapped as New Novo Japan Chief Novo Nordisk rang up record revenue in Japan in 2022 with sales surging 9.5% year on year to 119.6 billion yen, spurred primarily by its GLP-1 agents Ozempic (semaglutide injection) and...read more